Trial to Test Safety of Adding Capivasertib to a Standard Leukemia Treatment Regimen
Phase 1/2
104
about 6 years
18+
1 site in IL
What this study is about
Researchers are testing the safety of adding capivasertib to a standard leukemia treatment regimen. The trial will test different doses of capivasertib in adults with leukemia and lymphoma, along with venetoclax and chemotherapy. It aims to find the safest dose of capivasertib for this combination therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Blinatumomab
- 2.Take Capivasertib
- 3.Take Nelarabine
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
blinatumomab, capivasertib, nelarabine, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), venetoclax
injection, intravenous, oral (Oral Tablet), injection (Injection), infusion, oral
Secondary: Overall survival [Cohort 2 and 3], Progression free survival [All Cohorts], Rate of CR with measurable residual disease (MRD) negativity [Cohort 1], Rate of clinical remission (CR) [Cohort 1]
Oncology